S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in

Bristol-Myers Squibb Stock Forecast, Price & News

+0.38 (+0.59 %)
(As of 01/22/2021 12:00 AM ET)
Today's Range
Now: $64.56
50-Day Range
MA: $62.70
52-Week Range
Now: $64.56
Volume9.07 million shs
Average Volume12.07 million shs
Market Capitalization$146.08 billion
P/E RatioN/A
Dividend Yield3.05%
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. The company's products include Opdivo for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, it offers Reyataz, a protease inhibitor to treat human immunodeficiency virus (HIV); Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. The company has collaboration agreements with Pfizer, Otsuka, Ono, Nektar, GRYT Health, Ubiquigent Limited, Checkmate Pharmaceuticals, and Sensyne Health plc; clinical collaboration with NeoImmuneTech, Inc.; partnership with Astrazeneca Plc; a discovery collaboration with Insitro, Inc.; and collaboration with Schrödinger, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Bristol-Myers Squibb logo


Overall MarketRank

2.33 out of 5 stars

Medical Sector

14th out of 1,925 stocks

Pharmaceutical Preparations Industry

8th out of 773 stocks

Analyst Opinion: 2.4Community Rank: 2.6Dividend Strength: 2.5Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations



Sales & Book Value

Annual Sales$26.15 billion
Cash Flow$4.26 per share
Book Value$23.20 per share


Net Income$3.44 billion


Outstanding Shares2,262,690,000
Market Cap$146.08 billion
Next Earnings Date2/4/2021 (Confirmed)
+0.38 (+0.59 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BMY News and Ratings via Email

Sign-up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions

How has Bristol-Myers Squibb's stock price been impacted by Coronavirus?

Bristol-Myers Squibb's stock was trading at $108.24 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BMY stock has decreased by 40.4% and is now trading at $64.56.
View which stocks have been most impacted by COVID-19

Is Bristol-Myers Squibb a buy right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last twelve months. There are currently 4 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Bristol-Myers Squibb stock.
View analyst ratings for Bristol-Myers Squibb
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Bristol-Myers Squibb?

Wall Street analysts have given Bristol-Myers Squibb a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Bristol-Myers Squibb wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Larry J. Merlo's approval rating as Bristol-Myers Squibb's CEO?

6,978 employees have rated Bristol-Myers Squibb CEO Larry J. Merlo on Glassdoor.com. Larry J. Merlo has an approval rating of 37% among Bristol-Myers Squibb's employees. This puts Larry J. Merlo in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is Bristol-Myers Squibb's next earnings date?

Bristol-Myers Squibb is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Bristol-Myers Squibb

How can I listen to Bristol-Myers Squibb's earnings call?

Bristol-Myers Squibb will be holding an earnings conference call on Thursday, February 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb (NYSE:BMY) posted its quarterly earnings results on Tuesday, November, 10th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating the Zacks' consensus estimate of $1.49 by $0.14. The biopharmaceutical company earned $10.54 billion during the quarter, compared to analysts' expectations of $10.33 billion. Bristol-Myers Squibb had a positive return on equity of 27.48% and a negative net margin of 0.11%. The business's quarterly revenue was up 75.5% on a year-over-year basis. During the same period in the prior year, the firm posted $1.17 earnings per share.
View Bristol-Myers Squibb's earnings history

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb announced a quarterly dividend on Thursday, December 10th. Shareholders of record on Monday, January 4th will be paid a dividend of $0.49 per share on Monday, February 1st. This represents a $1.96 dividend on an annualized basis and a yield of 3.04%. The ex-dividend date of this dividend is Thursday, December 31st. This is an increase from Bristol-Myers Squibb's previous quarterly dividend of $0.45.
View Bristol-Myers Squibb's dividend history

Is Bristol-Myers Squibb a good dividend stock?

Bristol-Myers Squibb pays an annual dividend of $1.96 per share and currently has a dividend yield of 3.05%. Bristol-Myers Squibb does not yet have a strock track record of dividend growth. The dividend payout ratio of Bristol-Myers Squibb is 41.79%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Bristol-Myers Squibb will have a dividend payout ratio of 26.78% next year. This indicates that Bristol-Myers Squibb will be able to sustain or increase its dividend.
View Bristol-Myers Squibb's dividend history.

When did Bristol-Myers Squibb's stock split? How did Bristol-Myers Squibb's stock split work?

Shares of Bristol-Myers Squibb split on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were distributed to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of Bristol-Myers Squibb stock prior to the split would have 200 shares after the split.

What guidance has Bristol-Myers Squibb issued on next quarter's earnings?

Bristol-Myers Squibb updated its FY21 earnings guidance on Thursday, November, 5th. The company provided earnings per share (EPS) guidance of $7.15-7.45 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.41.

What price target have analysts set for BMY?

15 brokerages have issued 1-year price objectives for Bristol-Myers Squibb's shares. Their forecasts range from $65.00 to $88.00. On average, they anticipate Bristol-Myers Squibb's share price to reach $74.27 in the next twelve months. This suggests a possible upside of 15.0% from the stock's current price.
View analysts' price targets for Bristol-Myers Squibb
or view Wall Street analyst' top-rated stocks.

Who are some of Bristol-Myers Squibb's key competitors?

What other stocks do shareholders of Bristol-Myers Squibb own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bristol-Myers Squibb investors own include AbbVie (ABBV), AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Intel (INTC), NVIDIA (NVDA), CVS Health (CVS), Cisco Systems (CSCO) and Bank of America (BAC).

Who are Bristol-Myers Squibb's key executives?

Bristol-Myers Squibb's management team includes the following people:
  • Dr. Giovanni Caforio, Chairman & CEO (Age 56, Pay $6.22M)
  • Mr. David V. Elkins, Exec. VP & CFO (Age 53, Pay $3.62M)
  • Ms. Sandra Leung Esq., Exec. VP & Gen. Counsel (Age 60, Pay $2.92M)
  • Dr. Christopher S. Boerner, Exec. VP & Chief Commercialization Officer (Age 50, Pay $2.49M)
  • Mr. Rupert Vessey M.A., Exec. VP and Pres of Research & Early Devel. (Age 56, Pay $3.31M)
  • Mr. Paul von Autenried, Exec. VP & Chief Information Officer (Age 59)
  • Mr. Timothy Power, VP & Head of Investor Relations
  • Mr. Adam Dubow, Sr. VP, Chief Compliance & Ethics Officer (Age 54)
  • Ms. Ann M. Powell Judge, Exec. VP & Chief HR Officer (Age 55)
  • Mr. Louis S. Schmukler, Exec. VP and Pres of Global Product Devel. & Supply (Age 65)

What is Bristol-Myers Squibb's stock symbol?

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

Who are Bristol-Myers Squibb's major shareholders?

Bristol-Myers Squibb's stock is owned by many different retail and institutional investors. Top institutional investors include Gateway Investment Advisers LLC (0.04%), RNC Capital Management LLC (0.03%), State of Alaska Department of Revenue (0.03%), Dudley & Shanley Inc. (0.03%), Manning & Napier Group LLC (0.03%) and DNB Asset Management AS (0.02%). Company insiders that own Bristol-Myers Squibb stock include Adam Dubow, Autenried Paul Von, Dinesh C Paliwal, Ernest Mario, Giovanni Caforio, James J Loughlin, John E Elicker, Joseph Eid, Karen Murphy Santiago, Louis S Schmukler, Robert J Bertolini, Rupert Vessey, Sandra Leung, Terrie Curran and Theodore R Samuels II.
View institutional ownership trends for Bristol-Myers Squibb

Which major investors are selling Bristol-Myers Squibb stock?

BMY stock was sold by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Hexavest Inc., Woodstock Corp, Avantax Advisory Services Inc., Transform Wealth LLC, Manning & Napier Group LLC, Highland Capital Management LLC, and Viking Fund Management LLC. Company insiders that have sold Bristol-Myers Squibb company stock in the last year include Adam Dubow, Autenried Paul Von, Giovanni Caforio, John E Elicker, Joseph Eid, Louis S Schmukler, Rupert Vessey, and Sandra Leung.
View insider buying and selling activity for Bristol-Myers Squibb
or view top insider-selling stocks.

Which major investors are buying Bristol-Myers Squibb stock?

BMY stock was bought by a variety of institutional investors in the last quarter, including Dudley & Shanley Inc., Exchange Traded Concepts LLC, Bainco International Investors, Kestra Advisory Services LLC, Cumberland Advisors Inc., Gillespie Robinson & Grimm Inc., Rhenman & Partners Asset Management AB, and Paragon Capital Management LLC. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal, Ernest Mario, Robert J Bertolini, and Theodore R Samuels II.
View insider buying and selling activity for Bristol-Myers Squibb
or or view top insider-buying stocks.

How do I buy shares of Bristol-Myers Squibb?

Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bristol-Myers Squibb's stock price today?

One share of BMY stock can currently be purchased for approximately $64.56.

How big of a company is Bristol-Myers Squibb?

Bristol-Myers Squibb has a market capitalization of $146.08 billion and generates $26.15 billion in revenue each year. The biopharmaceutical company earns $3.44 billion in net income (profit) each year or $4.69 on an earnings per share basis. Bristol-Myers Squibb employs 30,000 workers across the globe.

What is Bristol-Myers Squibb's official website?

The official website for Bristol-Myers Squibb is www.bms.com.

How can I contact Bristol-Myers Squibb?

Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]

This page was last updated on 1/23/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.